openPR Logo
Press release

Artificial Intelligence to Fight Cardiovascular Disease

42.cx – Center of Excellence for Artificial Intelligence AG, based in Vienna, has just announced its partnership with The Heart Fund, a non-governmental organization to fight cardiovascular diseases. Together with The Heart Fund, 42.cx wants to solve public health challenges by modelizing diseases patterns through applied artificial intelligence to support THF doctors during their medical tasks. 42.cx will train its Supercomputer to generate predictive health models and to help to predict cardiovascular diseases by computer aided diagnosis. The generated prediction system will run on portable devices to disrupt healthcare in developing countries and to fight cardiovascular disease. “The Heart Fund combats cardiovascular diseases by offering access to care to millions of children in developing countries. For the first time in history with this partnership, artificial intelligence scientists have access to thousands of electrocardiograms (ECG), blood panels, evaluations and resulting diagnosis. This allows us to build more accurate models than ever before. With our technology a highly qualified diagnosis can be performed at thousands of different locations at the same time, around the clock anywhere in the world. It’s practically like having the know-how and knowledge of the best cardiologic surgeons combined and being present at the same time anywhere.,” explains Daniel Mattes, Founder and Executive Chairman of 42.cx. “We believe that only if true scientific power is being applied to the areas of research, ground-breaking results can be achieved. Our world-class team consists of scientists in the areas of Artificial Intelligence, mathematics, physics and economics, supported by data analysts and scientists, neural network engineers, machine learning scientists and software developers,” adds Mattes.

The Heart Fund saves the lives of children suffering from heart disease by empowering solutions and innovations that revolutionize access to care in developing countries. “The Heart Fund's vision is to deliver cardiac care to the world's most isolated areas by investing in technological innovation and sustainable scientific solutions. I am glad, that we found Daniel Mattes, as his AI technology is the perfect fit for our foundation,” says Dr. David Luu, founder of The Heart Fund.

The 42.cx – Center of Excellence for Artificial Intelligence has been developing AI applications over the last years in collaboration with a team of international renowned scientists from across the globe. The 42.cx research center combines expertise in computer science, symbolic computing, pattern recognition, computer vision and visual learning.

Press Images: http://42.cx/health-ai

About 42.cx
42.cx Center of Excellence for Artificial Intelligence AG is a scientific technology corporation that focuses on the commercialization of artificial intelligence. The core team of 42.cx consists of leading experts and scientists in the areas of Artificial Intelligence, mathematics, physics and economics, supported by data analysts and scientists, neural network engineers, machine learning scientists and software developers and is based in Vienna, Austria. Founder and Chairman of 42.cx is Daniel Mattes, a serial entrepreneur.
www.42.cx

About The Heart Fund
From pediatric open-heart surgery to the building of hospital planes, The Heart Fund collaborates with over one hundred volunteer experts and 120 private and institutional partners in Haiti, India, Mauritania and Côte d’Ivoire. Created in 2010 by Dr. David Luu, The Heart Fund is an international public charity that is a pioneer in technological innovation to combat cardiovascular diseases. Ambassadors of The Heart Fund are Didier Drogba, Rosario Dawson, Gary Dourdan, Willy Cartier, Alina Baikova, Eric Benet to name a few.
www.theheartfund.eu

About 42.cx
42.cx Center of Excellence for Artificial Intelligence AG is a scientific technology corporation that focuses on the commercialization of artificial intelligence. The core team of 42.cx consists of leading experts and scientists in the areas of Artificial Intelligence, mathematics, physics and economics, supported by data analysts and scientists, neural network engineers, machine learning scientists and software developers and is based in Vienna, Austria. Founder and Chairman of 42.cx is Daniel Mattes, a serial entrepreneur.
www.42.cx

42.cx - Center of Excellence for Artificial Intelligence AG
Gauermanngasse 2
A-1010 Wien
Austria

Press Contact
Markus Rumler
CMO 42.cx AG
press@42.cx

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Artificial Intelligence to Fight Cardiovascular Disease here

News-ID: 558490 • Views:

More Releases for Heart

Heart disease and Heart Attacks - Kaffailham.gr
Καρδιολόγος Αθηνα - https://kaffailham.gr When people talk about heart disease or heart attacks. The arteries that they are talking about are the arteries that actually provide blood to the heart. Remember the heart itself is a muscle. It itself needs oxygen. So you have these arteries right over here, the red tubes. Those are arteries. and then the blue ones are veins. They're taking the de-oxygenated blood away from the tissue
Artificial Heart Implant Market May See a Big Move | Major Giants Jarvik Heart, …
The Latest survey report on Artificial Heart Implant Market sheds lights on changing dynamics of each of the subsegments of Industry. As the shift to value continues, Artificial Heart Implant organizations have the dual challenge of increasing interoperability to improve clinical performance and the patient experience. Some of the companies listed in the study from complete survey list are Medtronic, Boston Scientific, Abbott, Terumo, B.Braun, SynCardia, BiVACOR, CARMAT, ReinHeart TAH
Heart Pump Device Market - Potential Innovations 2025 | Terumo, Jarvik Heart
Heart Pump Device Market: Snapshot Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices. These are surgically implanted and are used for temporarily supporting the functions of heart in people with weak heart or irregular blood flow. These devices are notably used as a bridge to cardiac transplantation for patients suffering with end stage heart failure. They can also be used in patients during and after
Congestive Heart Failure (Heart Failure)-Pipeline Review, H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure)-Pipeline Review, H2 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape. Heart failure is also known as congestive heart failure (CHF). CHF is a condition in which the heart is no longer able to pump out enough oxygen-rich blood. Symptoms include cough, fatigue, weakness, faintness, loss of appetite, swollen (enlarged) liver
Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Congestive Heart Failure (Heart Failure) - Pipeline Review, H2 2017, provides an overview of the Congestive Heart Failure (Heart Failure) (Cardiovascular) pipeline landscape. Heart failure is also known as congestive heart failure (CHF).
Congestive Heart Failure (Heart Failure) Market Research Report
Latest industry research report on: Congestive Heart Failure (Heart Failure) Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts GlobalData's clinical trial report, Congestive Heart Failure (Heart Failure) Global Clinical Trials Review, H1, 2017" provides an overview of Congestive Heart Failure (Heart Failure) clinical trials scenario. This report provides top line data relating to the clinical trials on Congestive Heart Failure (Heart Failure). Report includes an